Search
SIS-101-ADO
go.drugbank.com/drugs/DB18085ExperimentalSIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).[L48091]
Cerebrolysin
go.drugbank.com/drugs/DB16599InvestigationalProducts: Ambotonin 215,2 mg/ml - parenterale Lösung Injektionslösung/Konzentrat zur Herstellung einer InfusionslösungCyclomethicone 5
go.drugbank.com/drugs/DB11244ApprovedCyclomethicone 5 is member of cyclomethicone, which are a group of liquid methyl siloxanes that have low viscosity and high volatility. Cyclomethicones are cyclic in structure with a monomer backbone of one silicon and two oxygen atoms b...
Products: 3ce CR Eamy Water Proof Eye Liner 08 Les MiserablesImiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production.
International brands: Li DiProducts: Imikeraderm 50 mg/g CremeMomelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigationalMF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis. … It is a competitive inhibitor of JAK ATP binding.[A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis.
Adapalene
go.drugbank.com/drugs/DB00210ApprovedInvestigationalOn December 8th, 2008, Galderma Labs gained FDA approval for Epiduo®, a 0.1% adapalene, 2.5% BPO combination gel.[L12873] … It is also associated with _Cutibacterium acnes_ (also known as _Propionibacterium acnes_). Adapalene is a third-generation topical retinoid used for the treatment of acne vulgaris.
Mixtures: Clindap-TProducts: Proactiv MD Adapalene Acne Treatment, Deriva MS Aqueous Gel 0.1% w/wPirenoxine
go.drugbank.com/drugs/DB15945InvestigationalProducts: KARY UNI OPHTHALMIC SUSPENSION 0.05 mg/mlSimoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedSimoctocog alfa is a glycoprotein consisting of 1440 amino acids with an approximate molecular mass of 170 kDa, comprising the FVIII domains A1-A2 + A3-C1-C2 whereas the B-domain, present in the full-length … It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.
Products: NUWIQ 500 UI, NUWIQ 2000 UI